GlassScriptPhysician profile
Carrie Perry
NPI 1396285821
$6,187.03
in general payments reported to CMS, 2019-2025
28 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $560 · 2022: $1,512 · 2023: $1,711 · 2024: $1,207 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,299 · Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,299.02 |
| Food and Beverage | $1,815.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,923.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $573.28 | 2021-2023 | Enhertu, Imfinzi, Calquence |
| Stemline Therapeutics INC. | $407.21 | 2023-2025 | Orserdu |
| Merck Sharp & Dohme LLC | $358.28 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $327.58 | 2021-2023 | Enhertu, Injectafer |
| Eisai INC. | $305.05 | 2021-2023 | |
| Pfizer INC. | $279.10 | 2021-2025 | |
| Amgen INC. | $181.26 | 2021-2022 | |
| Tersera Therapeutics LLC | $108.50 | 2023-2025 | Zoladex |
| Gilead Sciences, INC. | $75.54 | 2023-2025 | Trodelvy |
| Lilly USA, LLC | $72.91 | 2021-2023 | Verzenio, Retevmo |
| Beigene USA, INC. | $55.75 | 2022-2023 | Brukinsa |
| Celgene Corporation | $55.21 | 2022 | |
| Emd Serono, INC. | $48.72 | 2022-2023 | Bavencio |
| Genentech USA, INC. | $48.50 | 2021-2023 | Phesgo, Perjeta, Kadcyla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $48.10 | 2022-2023 | Zejula, Jemperli |
| Seagen INC. | $47.03 | 2022-2023 | Tukysa |
| Genmab U.S., INC. | $36.86 | 2023 | Tivdak |
| Puma Biotechnology, INC. | $34.76 | 2022-2023 | |
| Array Biopharma INC | $34.74 | 2025 | Mektovi, Braftovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $30.74 | 2021-2022 | |
| Sobi, INC | $22.90 | 2023 | |
| G1 Therapeutics, INC. | $22.19 | 2022 | |
| Janssen Biotech, INC. | $20.83 | 2021 | |
| Eagle Pharmaceuticals, INC. | $18.69 | 2022 | |
| Abbvie INC. | $18.55 | 2025 | |
| Apellis Pharmaceuticals, INC. | $17.32 | 2023 | Empaveli |
| Ipsen Biopharmaceuticals, INC | $14.42 | 2023 | Tazverik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.